Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Natera Inc (NQ: NTRA )

130.81 +5.09 (+4.04%)
Streaming Delayed Price Updated: 10:07 AM EDT, Sep 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Natera Inc

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
New Study Validates Signatera™ in Endometrial Cancer
From Natera, Inc.
Via Business Wire
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
EQNX::TICKER_START (OTCQB:TDSGF),(TSXV:TELO),(NYSE:BMY),(NYSE:TMO),(NASDAQ:NTRA),(NASDAQ:NEO) EQNX::TICKER_END 
Via FinancialNewsMedia
Expert Ratings For Natera
Via Benzinga
Natera Inc. (NASDAQ: NTRA) Records 52-Week High Tuesday Morning
Via Investor Brand Network
The Analyst Landscape: 8 Takes On Natera
Via Benzinga
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
From FN Media Group LLC
Via GlobeNewswire
New Publication Demonstrates Signatera’s Ability to Risk Stratify and Detect Recurrence Early in Resected Stage I-II Lung Cancer
From Natera, Inc.
Via Business Wire
The Latest Analyst Ratings for Natera
Via Benzinga
Analyst Expectations for Natera's Future
Via Benzinga
Jury Rules in Favor of Natera in Patent Infringement Lawsuit Against CareDx; Awards $96.3 Million in Damages to Natera in Lost Profits and Past Royalties
From Natera, Inc.
Via Business Wire
Nature Medicine Publishes Two Studies Highlighting Signatera’s Clinical Utility in Patients with Gastrointestinal Malignancies
From Natera, Inc.
Via Business Wire
Natera Acquires Reproductive Health Assets from Invitae
From Natera, Inc.
Via Business Wire
Natera to Present New Data from the CIRCULATE-Japan and BESPOKE CRC Studies at ASCO GI 2024 Supporting Signatera’s Clinical Utility in CRC
From Natera, Inc.
Via Business Wire
Natera Hits A Nearly Two-Year High After Notching A Win In A Patent Battle
The company must pay $57 million in damages, but that's far less than expected. 
Via Investor's Business Daily
Topics Intellectual Property
Exposures Intellectual Property
Why DatChat Shares Are Trading Lower By Around 33%; Here Are 20 Stocks Moving Premarket
Shares of DatChat, Inc. (NASDAQ: DATS) fell sharply in pre-market trading after announcing a proposed underwritten public offering of common stock. DatChat shares dipped 33.1% to $2.13 in pre-market... 
Via Benzinga
Progress Software Posts Strong Q4 Results, Joins Impinj, REGENXBIO And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow Jones futures falling more than 100 points on Wednesday. Shares of Progress Software Corporation (NASDAQ: PRGS) rose in pre-market trading as... 
Via Benzinga
Topics Stocks
Exposures US Equities
Natera Provides Update on Ravgen Trial
From Natera, Inc.
Via Business Wire
Bull of the Day - NeoGenomics
But in late December, shares took a big hit on patent litigation with competitor Natera. Let's review the primary commercial business of NEO and then that will help put the legal news into context. 
Via Talk Markets
Topics Intellectual Property
Exposures Intellectual Property
Natera Announces Preliminary Fourth Quarter and Full Year 2023 Revenues
From Natera, Inc.
Via Business Wire
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Each week, Benzinga's Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface and warrant attention. 
Via Benzinga
Expedia To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Natera to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
From Natera, Inc.
Via Business Wire
US Court Prohibits NeoGenomics To Sell Type Of Diagnostic Kits To Detect Smaller Number Of Cancer Cells, Favoring Natera In Lawsuit
Shares of NeoGenomics Inc (NASDAQ: NEO) fell Thursday after the company received a preliminary injunction from a North Carolina district court, which prohibits the company from  
Via Benzinga
Natera Wins Preliminary Injunction in Patent Infringement Lawsuit Against NeoGenomics’ RaDaR Test
From Natera, Inc.
Via Business Wire
NATERA ALERT: Bragar Eagel & Squire, P.C. is Investigating Natera, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Natera Announces New Study Highlighting the Benefits of Signatera’s Unique Method of Quantifying ctDNA
From Natera, Inc.
Via Business Wire
Delaware Court Denies CareDx’s Motion for Summary Judgment on Two Natera Patents
From Natera, Inc.
Via Business Wire
Natera Presents New Signatera™ MRD Data Across Breast Cancer Treatment Settings at SABCS 2023
From Natera, Inc.
Via Business Wire
Top 5 Health Care Stocks That May Collapse In November
As of Nov. 17, 2023, five stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. 
Via Benzinga
Natera Announces Real-World Data Collaboration with Merck
From Natera, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.